Literature DB >> 12443671

CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.

X P Ioannou1, S M Gomis, B Karvonen, R Hecker, L A Babiuk, S van Drunen Littel-van den Hurk.   

Abstract

Vaccine adjuvants must have the capacity to increase protective immune responses with minimal side effects. Conventional adjuvants not only cause undesirable tissue site reactions, but often induce T-helper type 2 (Th2)-biased responses which may be undesirable in certain disease scenarios. Oligodeoxynucleotides containing unmethylated CpG dinucleotides (CpG ODN) are novel adjuvants known to promote Th1-type immune responses. In this study, we compared various mineral oil, metabolizable oil and non-oil adjuvants alone and in combination with CpG ODN for their ability to augment immune responses to a truncated secreted form of bovine herpesvirus (BHV) glycoprotein D (tgD). All adjuvants tested induced Th2-biased immune responses characterized by a predominance of serum IgG1 as well as interleukin-4 (IL-4) production by in vitro stimulated splenocytes. The inclusion of CpG ODN in these formulations not only increased immune responses, but more importantly enhanced serum IgG2a levels and production of interferon-gamma (IFN-gamma) by splenocytes, indicating a more balanced or Th1-type response. The use of a mineral oil-based adjuvant at reduced doses in combination with CpG ODN attenuated the tissue damage while not compromising the magnitude of the immune response in both mice and sheep. In addition, reduced amounts of mineral oil combined with CpG ODN induced a more balanced Th1/Th2 immune response than the mineral oil used alone. Our results clearly demonstrate that CpG ODN can be used to enhance magnitude and balance of an immune response while reducing the amount of mineral oil and hence undesirable side effects of vaccine adjuvants.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12443671     DOI: 10.1016/s0264-410x(02)00378-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Therapeutic Chlamydophila abortus and C. pecorum vaccination transiently reduces bovine mastitis associated with Chlamydophila infection.

Authors:  Carolin Biesenkamp-Uhe; Yihang Li; Hans-Robert Hehnen; Konrad Sachse; Bernhard Kaltenboeck
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

2.  Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

Authors:  Christopher B Fox; Susan L Baldwin; Thomas S Vedvick; Evelina Angov; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2012-08-15

3.  Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.

Authors:  M Oumouna; J W Mapletoft; B C Karvonen; L A Babiuk; S van Drunen Littel-van den Hurk
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Effect of a DNA-based immunostimulant on growth, performance, and expression of inflammatory and immune mediators in beef calves abruptly weaned and introduced to a complete ration.

Authors:  Amelia R Woolums; Brandi B Karisch; Jane A Parish; Jooyoun Park; Keun Seok Seo; Peres Badial; Steven C Olsen
Journal:  J Anim Sci       Date:  2019-01-01       Impact factor: 3.159

5.  Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models.

Authors:  Yi-Ping Li; Hye-Na Kang; Lorne-A Babiuk; Qiang Liu
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

6.  CpG DNA induces protective antiviral immune responses in Atlantic salmon (Salmo salar L.).

Authors:  Jorunn B Jørgensen; Lill-Heidi Johansen; Kari Steiro; Audny Johansen
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

8.  Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.

Authors:  S Munir Alam; Richard M Scearce; Robert J Parks; Kelly Plonk; Steven G Plonk; Laura L Sutherland; Miroslaw K Gorny; Susan Zolla-Pazner; Stacie Vanleeuwen; M Anthony Moody; Shi-Mao Xia; David C Montefiori; Georgia D Tomaras; Kent J Weinhold; Salim Abdool Karim; Charles B Hicks; Hua-Xin Liao; James Robinson; George M Shaw; Barton F Haynes
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 9.  Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

Authors:  Hidekazu Shirota; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2013-11-26       Impact factor: 5.217

10.  Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine.

Authors:  Cunbao Liu; Pengwei Huang; Dandan Zhao; Ming Xia; Weiming Zhong; Xi Jiang; Ming Tan
Journal:  Vaccine       Date:  2020-12-11       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.